Biofarm (BSE:BIO) Cash Flow for Lease Financing: lei0.0 Mil (TTM As of Mar. 2026)


BSE:BIO Biofarm SA BSE:BIO
70 GF Score
Price lei1.49
GF Value lei0.86
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm Cash Flow for Lease Financing?

Biofarm BSE:BIO +0.34% 70 Cash Flow for Lease Financing is lei0.0 Mil as of Mar. 2026. GuruFocus rates BSE:BIO with a GF Score™ of 70/100 and a GF Value™ of lei0.86 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Biofarm's Cash Flow for Lease Financing for the three months ended in Mar. 2026 was lei0.0 Mil. Biofarm's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.0 Mil.

Compared with last quarter (lei0.0 Mil in Dec. 2025 ), Biofarm's Cash Flow for Lease Financing remained the same in Mar. 2026 (lei0.0 Mil).

Biofarm Cash Flow for Lease Financing Historical Data

* Premium members only.

The historical data trend for Biofarm's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Cash Flow for Lease Financing Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BSE:BIO
70GF Score
Biofarm SA BSE:BIO
Cash Flow for Lease Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Lease Financing of lei0.0 Mil mean?
Biofarm (BSE:BIO) has a Cash Flow for Lease Financing of lei0.0 Mil as of Mar. 2026. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Biofarm and its competitors.
Is Biofarm's Cash Flow for Lease Financing too high?
Biofarm's current Cash Flow for Lease Financing is lei0.0 Mil. Overall, Biofarm has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Cash Flow for Lease Financing compare to ZTS and UTHR?
Biofarm's Cash Flow for Lease Financing of lei0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Lease Financing for a Drug Manufacturers company?
A good Cash Flow for Lease Financing depends on the Drug Manufacturers industry context. However, Cash Flow for Lease Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Lease Financing mean?
A high Cash Flow for Lease Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing. View historical data on Biofarm and its competitors. Biofarm's current Cash Flow for Lease Financing is lei0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.86, compared to a current price of lei1.49 — trading 72.7% above its estimated fair value. The current Cash Flow for Lease Financing is lei0.0 Mil. Biofarm's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Lease Financing calculated?
Cash Flow for Lease Financing is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Cash Flow for Lease Financing is lei0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.49 is trading 72.7% above its estimated GF Value™ of lei0.86. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Cash Flow for Lease Financing: lei0.0 Mil
  • GF Value™: lei0.86 vs. price of lei1.49 (72.7% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
70GF Score

Get the complete analysis for BSE:BIO

Cash Flow for Lease Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.49
Price
lei0.86
GF Value